Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line
Publication: Annals of Internal Medicine
Volume 132, Number 11
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-7.
2.
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab A, et al . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45.
3.
Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, et al . Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40:3147-54.
4.
Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-22.
5.
Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood. 1998;92:1184-90.
6.
Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al . Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-91.
7.
Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns , et al . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-74.
8.
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-33.
9.
Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al . Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-32.
10.
Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al . Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-76.
11.
Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al . Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-81.
12.
Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al . Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2(3):457-70.
13.
Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al . Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-803.
14.
Kaminski MS, Gribbin T, Estes J, Ross CW, Regan D, Zasadny K, et al . I-131 anti-B1 antibody for previously untreated follicular lymphoma: clinical and molecular remissions [Abstract]. Proc Am Soc Clin Oncol. 1998;17:2a.
15.
Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al . Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-24.
16.
Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al . Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-40.
17.
Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, et al . Follow-up of relapsed B cell lymphoma patients treated with I-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-8.
18.
DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al . Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-56.
19.
Juweid M, Sharkey RM, Marlowitz A, Behr T, Swayne LC, Dunn R, et al . Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995;55:5899-907.
20.
Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al . Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-75.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 132 • Number 11 • 6 June 2000
Pages: 916 - 918
History
Published in issue: 6 June 2000
Published online: 15 August 2000
Keywords
- Allergy and immunology
- Antibodies
- Antigens
- B cells
- Cancers and neoplasms
- Cell biology
- Cells
- Chemotherapy
- Clinical immunology
- Drug therapy
- Health care
- Hematologic malignancies
- Hematology and oncology
- Immune physiology
- Immune system proteins
- Immunology
- Lymphocytes
- Lymphoma
- Prevention, policy, and public health
- Research and reporting methods
- Surgery
- Transplantation
- White blood cells
Copyright
© 2000 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line. Ann Intern Med.2000;132:916-918. doi:10.7326/0003-4819-132-11-200006060-00012
Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line. Ann Intern Med.2000;132:916-918. doi:10.7326/0003-4819-132-11-200006060-00012
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.